Clinical trial

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-12-21

PhasePHASE4

Study timeline

Study start (actual)2024-12-21Date precision: day

Registry last updated2026-01-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes (T2DM)unresolved

Interventions

SGLT-2 inhibitorDRUG

GLP1-RADRUG

Sponsors & collaborators

MaryAnn Banerjilead sponsor

The New York Community Trustcollaborator

Mapped research locations

BrooklynNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07325435 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.